Simulations Plus（SLP）株式概要Simulations Plus, Inc.は、人工知能と機械学習ベースの技術を活用したモデリングとシミュレーション、分子特性予測のための創薬・医薬品開発ソフトウェアを世界中で開発しています。 詳細SLP ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長3/6過去の実績0/6財務の健全性6/6配当金0/6報酬当社が推定した公正価値より46.2%で取引されている 収益は年間152.82%増加すると予測されています リスク分析リスクチェックの結果、SLP 、リスクは検出されなかった。すべてのリスクチェックを見るSLP Community Fair Values Create NarrativeSee what 20 others think this stock is worth. Follow their fair value or set your own to get alerts.Analyst Price TargetsAN9.6% undervaluedAnalystLowTarget•22d agoBiopharma Budget And Pricing Will Curb Margins But Yield Promise1101AN53.3% undervaluedAnalystHighTarget•11mo agoAI Integration And Cloud Platforms Will Unlock In Silico Opportunities700AN35.2% undervaluedAnalystConsensusTarget•4mo agoSLP: Upcoming Earnings Guidance And Index Changes Will Drive Renewed Optimism14707Top Analyst NarrativesAN9.6% undervaluedAnalystLowTarget•22d agoBiopharma Budget And Pricing Will Curb Margins But Yield Promise1101AN53.3% undervaluedAnalystHighTarget•11mo agoAI Integration And Cloud Platforms Will Unlock In Silico Opportunities700AN35.2% undervaluedAnalystConsensusTarget•4mo agoSLP: Upcoming Earnings Guidance And Index Changes Will Drive Renewed Optimism14707View all narrativesSimulations Plus, Inc. 競合他社SOPHiA GENETICSSymbol: NasdaqGS:SOPHMarket cap: US$336.0mLifeMDSymbol: NasdaqGM:LFMDMarket cap: US$208.0mClaritevSymbol: NYSE:CTEVMarket cap: US$276.2mTruBridgeSymbol: NasdaqGS:TBRGMarket cap: US$383.9m価格と性能株価の高値、安値、推移の概要Simulations Plus過去の株価現在の株価US$14.4752週高値US$34.0152週安値US$11.09ベータ1.281ヶ月の変化-3.34%3ヶ月変化18.51%1年変化-54.35%3年間の変化-67.13%5年間の変化-72.32%IPOからの変化952.36%最新ニュースナラティブの更新 • Apr 29SLP: AI Regulatory Collaborations And Modest Growth Outlook Will Shape Balanced FutureAnalysts have maintained their $16.00 price target for Simulations Plus, noting that slightly adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E broadly offset one another in their updated models. What's in the News Announced a funded research collaboration with Lonza Group and the U.S. Food and Drug Administration (FDA) to develop a mechanistic framework for predicting in vivo performance of amorphous solid dispersion drug products, with the aim of supporting model informed drug development and potentially reducing reliance on some clinical bioequivalence studies (Key Developments).お知らせ • Apr 24Simulations Plus, Inc. Announces Collaboration with Lonza Group Ag and U.S. Food and Drug Administration to Advance Predictive Frameworks for Complex Oral Drug ProductsSimulations Plus, Inc. had announced a funded research collaboration with Lonza Group AG and the U.S. Food and Drug Administration to develop and validate a mechanistic, predictive framework for assessing the in vivo performance of amorphous solid dispersion drug products. Mechanistic modeling approach and experimental integration designed to improve early risk identification, strengthen regulatory confidence, and expand AI-enabled workflows connecting data to decision-making. The collaboration evaluates whether advanced in vitro dissolution systems—particularly those incorporating dynamic gastrointestinal physiology—combined with mechanistic physiologically based biopharmaceutics modeling, can reliably predict key in vivo outcomes, including food effects and the impact of elevated gastric pH conditions. By establishing and validating these predictive capabilities, the collaboration aims to provide a scientific foundation for reducing reliance on certain clinical bioequivalence studies while maintaining the rigor and transparency required by regulators. Lonza will lead experimental work, including in vitro dissolution testing under fasted, fed, and elevated gastric pH conditions using advanced systems such as Controlled Transfer Dissolution, as well as the characterization and, where needed, manufacturing of amorphous solid dispersion formulation variants. Simulations Plus will lead the development and validation of in vitro–in vivo extrapolation frameworks using its DDDPlus® and GastroPlus® platforms, translating experimental data into predictions of in vivo pharmacokinetics and supporting virtual bioequivalence assessments. At the same time, it creates new opportunities to extend these capabilities into grounded AI-enabled workflow environments, where data, mechanistic models, and simulation outputs will be more directly connected. The Company will also contribute to interpretation within a regulatory context, ensuring alignment with evolving expectations for model-informed drug development. This work is supported in part through FDA funding and includes ongoing engagement with FDA scientists to directly align with regulatory priorities to advance model-informed drug development, modernize bioequivalence assessment for complex products, and reduce unnecessary reliance on human studies. By combining regulatory collaboration with open, non-proprietary data and validated methods based on real-world, FDA-approved amorphous solid dispersion products, the initiative is intended to inform future regulatory approaches and support broader adoption of science-based alternatives.お知らせ • Apr 21Simulations Plus Inc Announces Completion of 2026 Spring School Global Training InitiativeSimulations Plus, Inc. announced the successful completion of its 2026 Spring School, a global training initiative designed to expand access to model-informed drug development (MIDD) and strengthen the scientific foundation of the industry’s future workforce. More than 1,400 scientists from industry, academia, and regulatory agencies from over 65 countries participated in the week-long program, reflecting the high demand for expert-led training as modeling and simulation increasingly become standard for drug development strategy, regulatory engagement, and clinical execution. Held from March 23 to 27, 2026, the Spring School program offered two tracks: GastroPlus Spring School: From PBPK Basics to Biopharmaceutics Applications, and MonolixSuite Spring School: High-Impact Pharmacometrics Case Studies. Both tracks included interactive lectures, hands-on exercises, and live Q&A sessions led by Simulations Plus experts. Simulations Plus has a long-standing commitment to education. In addition to its Spring School, the Company has previously offered Summer and Autumn Schools focused on PK/PD modeling. The most recent Autumn School was the first program to offer a second track focused on PBPK modeling. In addition to these programs, Simulations Plus is widely known for its University+ program, which provides free academic access to modeling and simulation software for thousands of students and educators worldwide. Together, these initiatives form a cornerstone of the Company’s global educational outreach—helping expand the adoption of model-informed approaches and strengthening the pipeline of scientists equipped to apply these methods across the drug development lifecycle.Seeking Alpha • Apr 12Simulations Plus: Down Substantially, Not An Automatic BuySummary Simulations Plus trades at decade lows as investors question growth and AI disruption risks. SLP's Q2 sales grew 8% to $24.3M, but the full-year revenue outlook is flat to up 4%, with earnings guidance down. Valuation has compressed to 2.5x sales and ~20x realistic earnings, supported by a $42M net cash position. Despite improved margins and lower multiples, lack of growth and AI uncertainty keep me cautious on Simulations Plus. Read the full article on Seeking Alphaナラティブの更新 • Apr 12SLP: AI Collaborations With Pharma And Regulators Will Drive Long-Term UpsideAnalysts have reduced their price target for Simulations Plus from $20 to $16, citing updated assumptions that combine lower revenue growth expectations with a higher projected profit margin and a meaningfully lower future P/E multiple. What's in the News Simulations Plus announced collaboration programs with three large pharmaceutical companies to apply artificial intelligence within modeling workflows across the drug development lifecycle, using platforms such as GastroPlus, MonolixSuite, ADMET Predictor, and Thales (Key Developments).Reported Earnings • Apr 10Second quarter 2026 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2026 results: EPS: US$0.23 (up from US$0.15 in 2Q 2025). Revenue: US$24.3m (up 8.3% from 2Q 2025). Net income: US$4.54m (up 48% from 2Q 2025). Profit margin: 19% (up from 14% in 2Q 2025). Revenue exceeded analyst estimates by 12%. Earnings per share (EPS) also surpassed analyst estimates by 11%. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 79 percentage points per year, which is a significant difference in performance.最新情報をもっと見るRecent updatesナラティブの更新 • Apr 29SLP: AI Regulatory Collaborations And Modest Growth Outlook Will Shape Balanced FutureAnalysts have maintained their $16.00 price target for Simulations Plus, noting that slightly adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E broadly offset one another in their updated models. What's in the News Announced a funded research collaboration with Lonza Group and the U.S. Food and Drug Administration (FDA) to develop a mechanistic framework for predicting in vivo performance of amorphous solid dispersion drug products, with the aim of supporting model informed drug development and potentially reducing reliance on some clinical bioequivalence studies (Key Developments).お知らせ • Apr 24Simulations Plus, Inc. Announces Collaboration with Lonza Group Ag and U.S. Food and Drug Administration to Advance Predictive Frameworks for Complex Oral Drug ProductsSimulations Plus, Inc. had announced a funded research collaboration with Lonza Group AG and the U.S. Food and Drug Administration to develop and validate a mechanistic, predictive framework for assessing the in vivo performance of amorphous solid dispersion drug products. Mechanistic modeling approach and experimental integration designed to improve early risk identification, strengthen regulatory confidence, and expand AI-enabled workflows connecting data to decision-making. The collaboration evaluates whether advanced in vitro dissolution systems—particularly those incorporating dynamic gastrointestinal physiology—combined with mechanistic physiologically based biopharmaceutics modeling, can reliably predict key in vivo outcomes, including food effects and the impact of elevated gastric pH conditions. By establishing and validating these predictive capabilities, the collaboration aims to provide a scientific foundation for reducing reliance on certain clinical bioequivalence studies while maintaining the rigor and transparency required by regulators. Lonza will lead experimental work, including in vitro dissolution testing under fasted, fed, and elevated gastric pH conditions using advanced systems such as Controlled Transfer Dissolution, as well as the characterization and, where needed, manufacturing of amorphous solid dispersion formulation variants. Simulations Plus will lead the development and validation of in vitro–in vivo extrapolation frameworks using its DDDPlus® and GastroPlus® platforms, translating experimental data into predictions of in vivo pharmacokinetics and supporting virtual bioequivalence assessments. At the same time, it creates new opportunities to extend these capabilities into grounded AI-enabled workflow environments, where data, mechanistic models, and simulation outputs will be more directly connected. The Company will also contribute to interpretation within a regulatory context, ensuring alignment with evolving expectations for model-informed drug development. This work is supported in part through FDA funding and includes ongoing engagement with FDA scientists to directly align with regulatory priorities to advance model-informed drug development, modernize bioequivalence assessment for complex products, and reduce unnecessary reliance on human studies. By combining regulatory collaboration with open, non-proprietary data and validated methods based on real-world, FDA-approved amorphous solid dispersion products, the initiative is intended to inform future regulatory approaches and support broader adoption of science-based alternatives.お知らせ • Apr 21Simulations Plus Inc Announces Completion of 2026 Spring School Global Training InitiativeSimulations Plus, Inc. announced the successful completion of its 2026 Spring School, a global training initiative designed to expand access to model-informed drug development (MIDD) and strengthen the scientific foundation of the industry’s future workforce. More than 1,400 scientists from industry, academia, and regulatory agencies from over 65 countries participated in the week-long program, reflecting the high demand for expert-led training as modeling and simulation increasingly become standard for drug development strategy, regulatory engagement, and clinical execution. Held from March 23 to 27, 2026, the Spring School program offered two tracks: GastroPlus Spring School: From PBPK Basics to Biopharmaceutics Applications, and MonolixSuite Spring School: High-Impact Pharmacometrics Case Studies. Both tracks included interactive lectures, hands-on exercises, and live Q&A sessions led by Simulations Plus experts. Simulations Plus has a long-standing commitment to education. In addition to its Spring School, the Company has previously offered Summer and Autumn Schools focused on PK/PD modeling. The most recent Autumn School was the first program to offer a second track focused on PBPK modeling. In addition to these programs, Simulations Plus is widely known for its University+ program, which provides free academic access to modeling and simulation software for thousands of students and educators worldwide. Together, these initiatives form a cornerstone of the Company’s global educational outreach—helping expand the adoption of model-informed approaches and strengthening the pipeline of scientists equipped to apply these methods across the drug development lifecycle.Seeking Alpha • Apr 12Simulations Plus: Down Substantially, Not An Automatic BuySummary Simulations Plus trades at decade lows as investors question growth and AI disruption risks. SLP's Q2 sales grew 8% to $24.3M, but the full-year revenue outlook is flat to up 4%, with earnings guidance down. Valuation has compressed to 2.5x sales and ~20x realistic earnings, supported by a $42M net cash position. Despite improved margins and lower multiples, lack of growth and AI uncertainty keep me cautious on Simulations Plus. Read the full article on Seeking Alphaナラティブの更新 • Apr 12SLP: AI Collaborations With Pharma And Regulators Will Drive Long-Term UpsideAnalysts have reduced their price target for Simulations Plus from $20 to $16, citing updated assumptions that combine lower revenue growth expectations with a higher projected profit margin and a meaningfully lower future P/E multiple. What's in the News Simulations Plus announced collaboration programs with three large pharmaceutical companies to apply artificial intelligence within modeling workflows across the drug development lifecycle, using platforms such as GastroPlus, MonolixSuite, ADMET Predictor, and Thales (Key Developments).Reported Earnings • Apr 10Second quarter 2026 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2026 results: EPS: US$0.23 (up from US$0.15 in 2Q 2025). Revenue: US$24.3m (up 8.3% from 2Q 2025). Net income: US$4.54m (up 48% from 2Q 2025). Profit margin: 19% (up from 14% in 2Q 2025). Revenue exceeded analyst estimates by 12%. Earnings per share (EPS) also surpassed analyst estimates by 11%. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 79 percentage points per year, which is a significant difference in performance.お知らせ • Mar 27Simulations Plus, Inc. to Report Q2, 2026 Results on Apr 09, 2026Simulations Plus, Inc. announced that they will report Q2, 2026 results After-Market on Apr 09, 2026分析記事 • Feb 08Simulations Plus, Inc.'s (NASDAQ:SLP) 26% Share Price Plunge Could Signal Some RiskSimulations Plus, Inc. ( NASDAQ:SLP ) shareholders won't be pleased to see that the share price has had a very rough...分析記事 • Feb 06Is There An Opportunity With Simulations Plus, Inc.'s (NASDAQ:SLP) 38% Undervaluation?Key Insights Using the 2 Stage Free Cash Flow to Equity, Simulations Plus fair value estimate is US$22.72 Simulations...Buy Or Sell Opportunity • Jan 30Now 24% undervalued after recent price dropOver the last 90 days, the stock has fallen 1.8% to US$16.87. The fair value is estimated to be US$22.06, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Meanwhile, the company became loss making.Price Target Changed • Jan 22Price target increased by 10% to US$24.67Up from US$22.33, the current price target is an average from 3 analysts. New target price is 19% above last closing price of US$20.74. Stock is down 38% over the past year. The company is forecast to post earnings per share of US$0.54 next year compared to a net loss per share of US$3.22 last year.Reported Earnings • Jan 09First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2026 results: EPS: US$0.034 (up from US$0.01 in 1Q 2025). Revenue: US$18.4m (down 2.7% from 1Q 2025). Net income: US$676.0k (up 228% from 1Q 2025). Profit margin: 3.7% (up from 1.1% in 1Q 2025). Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) missed analyst estimates by 63%. Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 90 percentage points per year, which is a significant difference in performance.お知らせ • Jan 09Simulations Plus, Inc. Reaffirms Earnings Guidance for Fiscal 2026Simulations Plus, Inc. reaffirmed earnings guidance for Fiscal 2026. For the period, the company expects Revenue to be in the range of $79 Million to $82 Million.ナラティブの更新 • Jan 07SLP: Reaffirmed Guidance And AI Roadmap Will Support Further UpsideAnalysts have trimmed their price target on Simulations Plus to about US$22.33 per share, reflecting a slightly higher discount rate and P/E assumptions that point to a more cautious stance on profitability. What's in the News Simulations Plus plans an Analyst and Investor Day focused on presenting its new product vision and AI solutions, highlighting where management is aiming future product development (Key Developments).お知らせ • Dec 30Simulations Plus, Inc., Annual General Meeting, Feb 12, 2026Simulations Plus, Inc., Annual General Meeting, Feb 12, 2026.お知らせ • Dec 17Simulations Plus, Inc. to Report Q1, 2026 Results on Jan 08, 2026Simulations Plus, Inc. announced that they will report Q1, 2026 results After-Market on Jan 08, 2026ナラティブの更新 • Dec 14SLP: Reinforced Revenue Outlook Will Drive Upside From Current LevelsAnalysts have modestly reduced their price target on Simulations Plus to approximately 22.33 dollars from 23 dollars. This reflects a recalibration of valuation multiples, even as they acknowledge stronger revenue growth and a significantly improved profit margin outlook.Reported Earnings • Dec 03Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: US$3.22 loss per share (down from US$0.50 profit in FY 2024). Revenue: US$79.2m (up 13% from FY 2024). Net loss: US$64.7m (down US$74.7m from profit in FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 1.1%. Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 82 percentage points per year, which is a significant difference in performance.お知らせ • Dec 02Simulations Plus, Inc. Reaffirms Revenue Guidance for Fiscal 2026Simulations Plus, Inc. reaffirmed revenue guidance for fiscal 2026. For the year, the company expects revenue of $79 million to $82 million.ナラティブの更新 • Nov 29SLP: Revenue Guidance Will Support Renewed Upside Despite Index ExclusionsAnalysts have maintained their price target for Simulations Plus at $23.00. They cited stable assumptions for revenue growth, profit margins, and valuation multiples in their latest assessment.ナラティブの更新 • Nov 15SLP: Revenue Forecasts Will Drive Potential Gains Despite Index RemovalsAnalysts have modestly adjusted their price target for Simulations Plus from $23.00 to $23.00. They cite subtle changes in assumptions around discount rate and profit margins, while maintaining steady core growth expectations.ナラティブの更新 • Nov 01SLP: Upcoming Earnings Guidance And Index Changes Will Drive Renewed OptimismAnalysts have adjusted their price target for Simulations Plus to $23.00. This reflects slight updates in their financial forecasts and expectations for future growth and profitability.分析記事 • Oct 28Simulations Plus, Inc. (NASDAQ:SLP) Shares Could Be 44% Below Their Intrinsic Value EstimateKey Insights Using the 2 Stage Free Cash Flow to Equity, Simulations Plus fair value estimate is US$32.42 Simulations...お知らせ • Oct 22+ 1 more updateSimulations Plus, Inc. to Report Q4, 2025 Results on Dec 01, 2025Simulations Plus, Inc. announced that they will report Q4, 2025 results at 4:00 PM, US Eastern Standard Time on Dec 01, 2025ナラティブの更新 • Oct 18Software Licensing Expansion And Integrated Services Will Ensure Future SuccessAnalysts have maintained the fair value estimate for Simulations Plus at $23.00. This reflects stable long-term growth expectations, even with only slight adjustments to underlying assumptions.ナラティブの更新 • Oct 03Software Licensing Expansion And Integrated Services Will Ensure Future SuccessAnalysts have revised their price target for Simulations Plus downward from $25.33 to $23.00, citing lower projected revenue growth and profit margins as key factors in their updated outlook. What's in the News Simulations Plus was removed from the S&P Composite 1500, S&P 1000, S&P 600, and S&P 600 Health Care indices (Key Developments).Recent Insider Transactions Derivative • Oct 02Director notifies of intention to sell stockWalter Woltosz intends to sell 20k shares in the next 90 days after lodging an Intent To Sell Form on the 1st of October. If the sale is conducted around the recent share price of US$15.07, it would amount to US$301k. Since December 2024, Walter's direct individual holding has decreased from 3.44m shares to 3.31m. There have been no trades via on-market transactions or options from company insiders in the last 12 months.分析記事 • Jul 31Some Simulations Plus, Inc. (NASDAQ:SLP) Shareholders Look For Exit As Shares Take 25% PoundingUnfortunately for some shareholders, the Simulations Plus, Inc. ( NASDAQ:SLP ) share price has dived 25% in the last...お知らせ • Jul 29Simulations Plus, Inc. and Institute of Medical Biology of the Polish Academy of Sciences Partnership Announces Results in Validation of ADMET Predictor Models with Enhanced AI Drug DesignSimulations Plus, Inc. announced that experimental results of its artificial intelligence-driven drug design (AIDD) collaboration with the Institute of Medical Biology of the Polish Academy of Sciences (IMB PAS) have been published in the American Chemical Society (ACS) Medical Chemical Letters. Simulations Plus and IMB PAS launched their collaboration in 2023 to use the AIDD module in ADMET Predictor®? to design novel RORg/RORgT ligands, molecules that impact gene expression related to inflammation and immune responses. Within three months, the two teams had developed models to predict RORg/RORg T ligand potency, designed potential ligands simultaneously optimized for potency, in vivo absorption, synthesizability, and ADMET risk, synthesized compounds, and completed initial in vitro potency and toxicity testing. The recently published results show that the vast majority of compounds tested had strong potency for the target that was close to or better than the values predicted by ADMET Predictor.Reported Earnings • Jul 15Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2025 results: US$3.35 loss per share (down from US$0.16 profit in 3Q 2024). Revenue: US$20.4m (up 9.8% from 3Q 2024). Net loss: US$67.3m (down US$70.5m from profit in 3Q 2024). Revenue exceeded analyst estimates by 4.0%. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 9.8% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 35 percentage points per year, which is a significant difference in performance.お知らせ • Jul 15Simulations Plus, Inc. Updates Earnings Guidance for the Fiscal Year 2025Simulations Plus, Inc. updated earnings guidance for the fiscal year 2025. For the year, the company expects revenue to be between $76 million to $80 million. Revenue growth to be between 9% to 14%.Major Estimate Revision • Jul 08Consensus EPS estimates fall by 16%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from US$81.7m to US$79.9m. EPS estimate also fell from US$0.363 per share to US$0.307 per share. Net income forecast to grow 39% next year vs 25% growth forecast for Healthcare Services industry in the US. Consensus price target down from US$36.25 to US$32.25. Share price fell 4.4% to US$17.51 over the past week.Recent Insider Transactions Derivative • Jul 02Director notifies of intention to sell stockWalter Woltosz intends to sell 60k shares in the next 90 days after lodging an Intent To Sell Form on the 1st of July. If the sale is conducted around the recent share price of US$17.45, it would amount to US$1.0m. Since September 2024, Walter's direct individual holding has decreased from 3.50m shares to 3.32m. There has only been one transaction (US$22k purchase) from insiders over the last 12 months.Valuation Update With 7 Day Price Move • Jun 17Investor sentiment deteriorates as stock falls 33%After last week's 33% share price decline to US$18.32, the stock trades at a forward P/E ratio of 35x. Average trailing P/E is 56x in the Healthcare Services industry in the US. Total loss to shareholders of 58% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$30.51 per share.Major Estimate Revision • Jun 13Consensus EPS estimates fall by 20%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from US$90.3m to US$85.8m. EPS estimate also fell from US$0.555 per share to US$0.443 per share. Net income forecast to grow 73% next year vs 25% growth forecast for Healthcare Services industry in the US. Consensus price target down from US$42.00 to US$36.25. Share price fell 31% to US$19.07 over the past week.分析記事 • Jun 13Simulations Plus, Inc.'s (NASDAQ:SLP) Stock Retreats 36% But Earnings Haven't Escaped The Attention Of InvestorsSimulations Plus, Inc. ( NASDAQ:SLP ) shares have had a horrible month, losing 36% after a relatively good period...New Risk • Jun 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Profit margins are more than 30% lower than last year (9.2% net profit margin).Buy Or Sell Opportunity • Jun 12Now 34% undervalued after recent price dropOver the last 90 days, the stock has fallen 23% to US$20.05. The fair value is estimated to be US$30.41, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has declined by 12%. Revenue is forecast to grow by 24% in 2 years. Earnings are forecast to grow by 120% in the next 2 years.お知らせ • Jun 12+ 1 more updateSimulations Plus, Inc. Provides Revenue Guidance for the Third Quarter and Full Year of Fiscal 2025Simulations Plus, Inc. provided revenue guidance for the third quarter and Full year of fiscal 2025. The Company expected to report third quarter fiscal 2025 revenue in the range of between $19 million and $20 million. Full year fiscal 2025 revenue is expected to range between $76 million and $80 million.お知らせ • Jun 05Simulations Plus, Inc. Releases ADMET Predictor 13Simulations Plus, Inc. announced the release of ADMET Predictor 13, its machine learning (ML) modeling platform for the design, optimization, and selection of new molecules during various stages of drug discovery. ADMET Predictor 13 features advancements in three main areas: First-to-invent advantage: clients can harness enhanced high-throughput PBPK (HT-PBPK) simulations--powered by GastroPlus®?--combined with the upgraded AI-driven drug design (AIDD) engine to enable faster, smarter decision-making at the intersection of chemistry and pharmacokinetics. Elevated predictive power: ADMET Predictor 13 offers an expanded suite of next-gen ADMET models, built with updated AI science and premium datasets, which boost accuracy across key endpoints and reinforce scientific rigor and validation. Enterprise-ready automation: with extended APIs, Python scripting support, and IT-friendly deployment capabilities, ADMET Predictor 13 delivers the automation and scalability required by today's data-centric R&D teams.Valuation Update With 7 Day Price Move • Jun 02Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to US$26.37, the stock trades at a forward P/E ratio of 41x. Average trailing P/E is 56x in the Healthcare Services industry in the US. Total loss to shareholders of 46% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$40.28 per share.Buy Or Sell Opportunity • May 21Now 21% undervaluedThe stock has been flat over the last 90 days, currently trading at US$31.70. The fair value is estimated to be US$40.00, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has declined by 12%. Revenue is forecast to grow by 36% in 2 years. Earnings are forecast to grow by 137% in the next 2 years.お知らせ • May 15Simulations Plus, Inc. Releases DILIsym 11Simulations Plus, Inc. announced the release of DILIsym 11, the latest version of its quantitative systems toxicology (QST) platform. DILIsym is a software platform designed to predict potential DILI hazards and provide insight into the mechanisms responsible for observed DILI responses. It is the most widely used QST modeling software for DILI prediction and is utilized as a source of QST modeling-based data assessed by the U.S. Food and Drug Administration's (FDA) DILIsym team. DILIsym 11 offers new pediatric representation for exploratory predictions regarding liver safety to children, and a new T-cell model that allows for better understanding of putative contributions of CD8+ T-cell mediated hepatocellular injury. It also includes improved representation of bile acid and cholestatic liver injury, updated antioxidant adaptation mechanisms, and more.分析記事 • May 07Are Investors Undervaluing Simulations Plus, Inc. (NASDAQ:SLP) By 28%?Key Insights The projected fair value for Simulations Plus is US$40.15 based on 2 Stage Free Cash Flow to Equity...Buy Or Sell Opportunity • May 06Now 28% undervalued after recent price dropOver the last 90 days, the stock has fallen 20% to US$29.01. The fair value is estimated to be US$40.17, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has declined by 12%. Revenue is forecast to grow by 36% in 2 years. Earnings are forecast to grow by 137% in the next 2 years.Price Target Changed • Apr 25Price target increased by 9.4% to US$46.60Up from US$42.60, the current price target is an average from 5 analysts. New target price is 31% above last closing price of US$35.50. Stock is down 21% over the past year. The company is forecast to post earnings per share of US$0.56 for next year compared to US$0.50 last year.お知らせ • Apr 21Simulations Plus, Inc. Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety StudiesSimulations Plus, Inc. announced its support of the U.S. Food and Drug Administration's (FDA) recently announced roadmap for reducing animal testing through the use of new approach methodologies (NAMs). Simulations Plus has long provided the software and consulting service expertise to successfully implement the FDA roadmap. The new FDA roadmap outlines a path to incorporate methodologies such as organ-on-a-chip, advanced in vitro assays, and computational modeling in preclinical safety studies, with an initial focus on monoclonal antibody (mAb) testing. Simulations Plus software platforms are utilized by mAb-focused researchers for key decision-making, including: GastroPlus accelerates the assessment of dosing and delivery strategies needed to achieve desired clinical endpoints, enabling researchers to reduce--and in some cases, eliminate--animal testing during non-clinical development. In addition, Simulations Plus' software and consulting services are regularly relied upon by researchers to predict efficacy and safety of compounds and prioritize top drug candidates for further development--contributing to a reduction in animal testing and more focused clinical trials. Simulations Plus' PBPK services team delivers high-value scientific expertise to help clients replace or reduce animal testing by developing and validating predictive PBPK models that integrate standard in vitro and in silico data to simulate human and animal pharmacometrics. Many organizations will need more than new modeling tools and in vitro systems. To follow the FDA roadmap, companies not currently incorporating NAMs into their development processes and timelines may also require consulting services, regulatory guidance and training on new tools.Seeking Alpha • Apr 16Simulations Plus: Benefiting From FDA Modernization And AISummary Simulations Plus, Inc. offers AI-based software tools for drug discovery and optimization, significantly reducing R&D time and costs for pharmaceutical research. SLP's diverse software portfolio, including GastroPlus and ADMET Predictor, and consulting services position it as a comprehensive partner in biotech development. Favorable regulatory changes by the FDA towards AI and non-animal testing methods boost SLP's market potential, despite its current high valuation. SLP's long-term outlook remains strong due to its innovative approach and the growing adoption of AI in drug testing, making it a "Buy" for long-term investors. Read the full article on Seeking Alpha分析記事 • Apr 13Simulations Plus, Inc.'s (NASDAQ:SLP) 25% Jump Shows Its Popularity With InvestorsSimulations Plus, Inc. ( NASDAQ:SLP ) shareholders would be excited to see that the share price has had a great month...Reported Earnings • Apr 04Second quarter 2025 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2025 results: EPS: US$0.15 (down from US$0.20 in 2Q 2024). Revenue: US$22.4m (up 23% from 2Q 2024). Net income: US$3.07m (down 24% from 2Q 2024). Profit margin: 14% (down from 22% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.3%. Earnings per share (EPS) also surpassed analyst estimates by 22%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings.お知らせ • Apr 04Simulations Plus, Inc. Provides Earnings Guidance for the Year 2025Simulations Plus, Inc. provided earnings guidance for the year 2025. For the year, the company expects revenue of $90 million to $93 million. Revenue growth of 28% to 33%.お知らせ • Mar 20Simulations Plus, Inc. to Report Q2, 2025 Results on Apr 03, 2025Simulations Plus, Inc. announced that they will report Q2, 2025 results After-Market on Apr 03, 2025Valuation Update With 7 Day Price Move • Feb 25Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to US$30.50, the stock trades at a forward P/E ratio of 59x. Average trailing P/E is 61x in the Healthcare Services industry in North America. Total loss to shareholders of 23% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$41.85 per share.分析記事 • Feb 08Why Investors Shouldn't Be Surprised By Simulations Plus, Inc.'s (NASDAQ:SLP) 29% Share Price SurgeSimulations Plus, Inc. ( NASDAQ:SLP ) shareholders would be excited to see that the share price has had a great month...Buy Or Sell Opportunity • Feb 06Now 21% undervaluedOver the last 90 days, the stock has risen 16% to US$35.58. The fair value is estimated to be US$44.98, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has declined by 7.1%. Revenue is forecast to grow by 41% in 2 years. Earnings are forecast to grow by 102% in the next 2 years.Major Estimate Revision • Jan 15Consensus EPS estimates fall by 38%The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate fell from US$0.763 to US$0.475 per share. Revenue forecast steady at US$90.4m. Net income forecast to grow 38% next year vs 19% growth forecast for Healthcare Services industry in the US. Consensus price target of US$49.00 unchanged from last update. Share price was steady at US$28.76 over the past week.Reported Earnings • Jan 08First quarter 2025 earnings: EPS misses analyst expectationsFirst quarter 2025 results: EPS: US$0.01 (down from US$0.098 in 1Q 2024). Revenue: US$18.9m (up 31% from 1Q 2024). Net income: US$206.0k (down 89% from 1Q 2024). Profit margin: 1.1% (down from 13% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 86%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 9.4% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 16% per year, which means it is performing significantly worse than earnings.分析記事 • Jan 08Capital Allocation Trends At Simulations Plus (NASDAQ:SLP) Aren't IdealIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. One common...お知らせ • Jan 08Simulations Plus, Inc. Provides Earnings Guidance for the Fiscal 2025Simulations Plus, Inc. provided earnings guidance for the fiscal 2025. For the period, the company expects Revenue to be in the range of $90 million to $93 million.Board Change • Jan 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 2 highly experienced directors. Independent Director Sharlene Evans was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Dec 24Simulations Plus, Inc., Annual General Meeting, Feb 13, 2025Simulations Plus, Inc., Annual General Meeting, Feb 13, 2025.お知らせ • Dec 20Simulations Plus, Inc. to Report Q1, 2025 Results on Jan 07, 2025Simulations Plus, Inc. announced that they will report Q1, 2025 results After-Market on Jan 07, 2025Valuation Update With 7 Day Price Move • Nov 25Investor sentiment improves as stock rises 16%After last week's 16% share price gain to US$32.74, the stock trades at a forward P/E ratio of 43x. Average trailing P/E is 57x in the Healthcare Services industry in North America. Total loss to shareholders of 30% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$47.71 per share.お知らせ • Nov 13Simulations Plus, Inc. and University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting InjectablesSimulations Plus, Inc. announced that it has been awarded a newly funded grant from the U.S. Food and Drug Administration (FDA) to use physiologically based pharmacokinetic (PBPK) approaches in GastroPlus to build and validate mechanistic in vitro-in vivo correlations (IVIVCs) for long-acting injectable (LAI) technologies through a joint proposal with the University of Connecticut’s School of Pharmacy, Department of Pharmaceutical Sciences. This project aims to use the GastroPlus PBPK platform to investigate the intricate relationship between LAI formulation critical quality attributes (CQAs) and physiological factors at the injection site to accurately predict in vivo drug release and absorption. Dr. Diane Burgess, Board of Trustees Distinguished Professor of Pharmaceutics and Pfizer Distinguished Endowed Chair of Pharmaceutical Technology at the University of Connecticut and her lab will generate in vitro and in vivo data for marketed LAI suspension products using novel discriminatory systems. The scientific team at Simulations Plus will use this data, along with additional inputs from research collaborators, to develop PBPK models and apply them to validate mechanistic IVIVCs. This effort is expected to lay the groundwork for a practical alternative to in vivo studies in establishing bioequivalence (BE) for additional LAI product technologies. FDA scientific and program staff will actively collaborate with the University of Connecticut, Simulations Plus, and select industry partners. Dr. Silva Ryan, with assistance from scientists at Simulations Plus, will coordinate the contract’s modeling and simulation activities. Funding for this collaboration is made possible by the FDA through grant award 1U01FD008304-01. Views expressed in this press release do not necessarily reflect the official policies of the Department of Health and Human Services; nor does any mention of trade names, commercial practices, or organizations imply endorsement by the United States Government.分析記事 • Nov 07We Think Simulations Plus' (NASDAQ:SLP) Healthy Earnings Might Be ConservativeDespite posting healthy earnings, Simulations Plus, Inc.'s ( NASDAQ:SLP ) stock has been quite weak. Along with the...Valuation Update With 7 Day Price Move • Oct 30Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to US$28.68, the stock trades at a forward P/E ratio of 45x. Average trailing P/E is 49x in the Healthcare Services industry in the US. Total loss to shareholders of 45% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$47.73 per share.新しいナラティブ • Oct 27Biosimulation Innovations And Tactical Acquisitions To Boost Drug Development Growth Integration and expansion into new markets drive revenue growth and improved profitability through increased efficiencies and enhanced offerings. Price Target Changed • Oct 27Price target decreased by 7.5% to US$52.75Down from US$57.00, the current price target is an average from 4 analysts. New target price is 72% above last closing price of US$30.68. Stock is down 9.7% over the past year. The company is forecast to post earnings per share of US$0.64 for next year compared to US$0.50 last year.Reported Earnings • Oct 24Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2024 results: EPS: US$0.50. Revenue: US$70.0m (up 18% from FY 2023). Net income: US$9.95m (flat on FY 2023). Profit margin: 14% (down from 17% in FY 2023). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.5%. Earnings per share (EPS) exceeded analyst estimates by 4.3%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Healthcare Services industry in the US.お知らせ • Oct 24Simulations Plus, Inc. Provides Earnings Guidance for Fiscal Year 2025Simulations Plus, Inc. provided earnings guidance for Fiscal year 2025. For the period, the company expects Revenue to be in the range of $90 million to $93 million.お知らせ • Oct 10Simulations Plus, Inc. to Report Q4, 2024 Results on Oct 23, 2024Simulations Plus, Inc. announced that they will report Q4, 2024 results After-Market on Oct 23, 2024お知らせ • Oct 08Simulations Plus and the University of Southern California Secure NIH Grant to Develop New AI Drug Discovery OfferingsSimulations Plus, Inc. announced the award of a new research grant from the National Institutes of Health (NIH), secured in partnership with the University of Southern California (USC) Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences. The grant will be used to evaluate novel computational methods that account for water-ligand interactions in drug discovery and that integrate with the Artificial Intelligence-driven Drug Design (AIDD) module in ADMET Predictor to offer a first-of-its-kind ligand-based virtual screening (LBVS) solution for pharmaceutical companies. For this award, Dr. Ian Haworth, Associate Professor and Vice Chair of Pharmacology and Pharmaceutical Sciences at the USC Mann School, and his lab will apply their previously developed algorithm (WATGEN) for the prediction of water positions in the unbound protein and protein-ligand complex. With support from the data scientists and software engineers at Simulations Plus, they will apply machine learning (ML) approaches to predict the pharmacophore features that will be used in ADMET Predictor’s proprietary 3D shape and feature matching algorithm. The team at Simulations Plus will productize the updated methods into the ADMET Predictor platform and validate it by designing drugs against defined targets using the AIDD module. Selected compounds will be synthesized and tested experimentally to highlight the technology’s applications.お知らせ • Aug 23Simulations Plus, Inc. Announces Executive Changes, Effective August 30, 2024Simulations Plus, Inc. announced the optimization of its business unit and leadership structure to support future growth following the company’s recent acquisitions. These actions will be effective August 30, 2024. The company announced the following leadership promotions and transitions: Steven Changwill be promoted to President, Quantitative Systems Pharmacology. Mr. Chang joined Simulations Plus in June 2023 with the acquisition of Immunetrics and served as its President and Chief Executive Officer since 2002. He is a successful technology entrepreneur with more than three decades of experience in identifying emerging market needs and combining state-of-the-art technologies and resources to meet those needs. Jenna Rousewill be promoted to President of the newly formed Adaptive Learning & Insights business unit. Ms. Rouse joined Simulations Plus with the acquisition of Pro-ficiency where, as Chief Markets Officer, Clinical, she spent five years driving the growth and engagement with the organization’s simulation-enabled training solutions for clinical trial optimization, competency development, and continuing medical education. Prior to joining Pro-ficiency, she spent 25 years in workforce development in regulated industries, with over 15 years dedicated to professional development and adult learning in clinical trials. Murry Alper will be promoted to President of the newly formed Medical Communications business unit. Mr. Alper joined Simulations Plus with the acquisition of Pro-ficiency. Mr. Alper brings almost 30 years of experience in the life sciences industry, with experience at both major developers, as well as on the agency side. Mr. Alper founded Caravel Group in 2006 after a decade in marketing and sales roles at Bristol-Myers Squibb and Genentech. He has co-founded multiple medical communications agencies and was Managing Partner of Compass Group Partners upon its purchase by Pro-ficiency in June of 2023. Sandra Suarez-Sharp, Ph.D., will transition to President, Regulatory Strategies Center of Excellence. Dr. Suarez-Sharp joined Simulations Plus in 2020 and has been instrumental in facilitating the Company’s regulatory support to clients. Prior to joining Simulations Plus, Dr. Suarez-Sharp had a long and successful career at the Food and Drug Administration, including roles in biopharmaceutics, bioequivalence, and clinical pharmacology. In her new role, she is responsible for expanding the Regulatory Strategies Center of Excellence to accelerate cross-selling opportunities driven by the rapidly growing demand for biosimulation solutions. The company also announced the following departures: Brett Howell, Ph.D., President, Quantitative Systems Pharmacology and Michael Raymer, President, Clinical Simulations & Medical Communications will be leaving Simulations Plus after assisting with the transition process.Seeking Alpha • Aug 22Simulations Plus: Declining Margins Are A ProblemSummary Simulations Plus growth is steady, but its margins continue to decline. This has been problematic due to the company's high valuation. Simulations Plus has suggested that the demand environment is improving, but its guidance implies a meaningful deceleration in organic growth. Simulations Plus likely needs to maintain its growth rate while improving margins before its share price moves higher. The decision to cut the company's dividend suggests that an improvement in margins and cash flows could be some way off. Read the full article on Seeking AlphaBuy Or Sell Opportunity • Aug 02Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 17% to US$38.60. The fair value is estimated to be US$49.11, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has declined by 3.6%. Revenue is forecast to grow by 53% in 2 years. Earnings are forecast to grow by 51% in the next 2 years.お知らせ • Aug 02Simulations Plus, Inc. Releases the latest version of its quantitative systems toxicology (QST) platform, DILIsym version XSimulations Plus, Inc. has released the latest version of its quantitative systems toxicology (QST) platform, DILIsym version X. Branded as DSX™?, the software is designed to support key drug development decisions by predicting potential drug-induced liver injury (DILI) risks. These predictions can guide go/no-go decisions, or the need to modify doses, which are vital to avoiding costly failed clinical trials. DSX offers a completely redesigned interface, tested by clients and consultants, that includes both command line and graphical interface options as well as a licensing option that enables scale-up on local or cloud cluster configurations. Four new exemplar compounds are included in this version of the software, as well as two new simulation populations that include variability in susceptibility to liver injury and biomarker-related parameters (ALT and bilirubin).Upcoming Dividend • Jul 22Upcoming dividend of US$0.06 per shareEligible shareholders must have bought the stock before 29 July 2024. Payment date: 05 August 2024. The company last paid an ordinary dividend in November 2013. The average dividend yield among industry peers is 1.1%.Seeking Alpha • Jul 10Simulations Plus: Steady Growth, But What About The Margins?Summary Simulations Plus, Inc. has seen stagnant stock trading despite impressive growth in the biosimulation market. Recent margin pressure and M&A activity raise concerns about management's ability to deliver. Acquisition of Pro-ficiency Holdings doubles the addressable market, but uncertainty remains about growth and margins amidst a demanding valuation. Read the full article on Seeking AlphaMajor Estimate Revision • Jul 09Consensus EPS estimates fall by 14%The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate fell from US$0.547 to US$0.47 per share. Revenue forecast steady at US$71.2m. Net income forecast to grow 28% next year vs 25% growth forecast for Healthcare Services industry in the US. Consensus price target of US$60.33 unchanged from last update. Share price fell 16% to US$39.57 over the past week.Declared Dividend • Jul 05Third quarter dividend of US$0.06 announcedShareholders will receive a dividend of US$0.06. Ex-date: 29th July 2024 Payment date: 5th August 2024 Dividend yield will be 0.6%, which is lower than the industry average of 0.9%.Reported Earnings • Jul 05Third quarter 2024 earnings: EPS in line with analyst expectations despite revenue beatThird quarter 2024 results: EPS: US$0.16 (down from US$0.20 in 3Q 2023). Revenue: US$18.5m (up 14% from 3Q 2023). Net income: US$3.14m (down 22% from 3Q 2023). Profit margin: 17% (down from 25% in 3Q 2023). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has fallen by 9% per year.お知らせ • Jul 03+ 1 more updateSimulations Plus, Inc. Updates Earnings Guidance for the Fiscal 2024Simulations Plus, Inc. updated earnings guidance for the fiscal 2024. The company maintained revenue of $69 million to $72 million. Diluted EPS of $0.46 - $0.48.Buy Or Sell Opportunity • Jul 01Now 12% overvalued after recent price riseOver the last 90 days, the stock has risen 20% to US$46.18. The fair value is estimated to be US$41.15, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has declined by 2.8%. Revenue is forecast to grow by 53% in 2 years. Earnings are forecast to grow by 69% in the next 2 years.Buy Or Sell Opportunity • Jun 21Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 12% to US$48.15. The fair value is estimated to be US$39.87, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has declined by 2.8%. Revenue is forecast to grow by 52% in 2 years. Earnings are forecast to grow by 69% in the next 2 years.お知らせ • Jun 19Simulations Plus, Inc. to Report Q3, 2024 Results on Jul 02, 2024Simulations Plus, Inc. announced that they will report Q3, 2024 results After-Market on Jul 02, 2024Major Estimate Revision • Jun 18Consensus EPS estimates fall by 17%, revenue upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from US$68.1m to US$70.8m. EPS estimate fell from US$0.657 to US$0.547 per share. Net income forecast to grow 29% next year vs 25% growth forecast for Healthcare Services industry in the US. Consensus price target up from US$55.33 to US$60.33. Share price rose 2.5% to US$47.21 over the past week.Price Target Changed • Jun 13Price target increased by 12% to US$60.33Up from US$53.67, the current price target is an average from 3 analysts. New target price is 24% above last closing price of US$48.62. Stock is up 3.4% over the past year. The company is forecast to post earnings per share of US$0.59 for next year compared to US$0.50 last year.お知らせ • Jun 13Simulations Plus, Inc. (NasdaqGS:SLP) acquired Pro-ficiency, LLC from NovaQuest Capital Management, L.L.C., QHP Capital, L.P. and Pro-ficiency’s minority shareholders for approximately $100 million.Simulations Plus, Inc. (NasdaqGS:SLP) acquired Pro-ficiency, LLC from NovaQuest Capital Management, L.L.C., QHP Capital, L.P. and Pro-ficiency’s minority shareholders for approximately $100 million on June 12, 2024. The transaction is expected to be accretive to fiscal 2025 EPS. The transaction is being funded from existing cash and investment resources. With approximately $119 million in cash and investments available, this acquisition allows Simulations to utilize the capital from August 2020 follow-on public offering. Procopio acted as legal counsel for Simulations Plus and Wyrick Robbins acted as legal counsel for Pro-ficiency and the sellers of Pro-ficiency. Simulations Plus, Inc. (NasdaqGS:SLP) completed the acquisition of Pro-ficiency, LLC from NovaQuest Capital Management, L.L.C., QHP Capital, L.P. and Pro-ficiency’s minority shareholders on June 12, 2024.お知らせ • May 16Simulations Plus Releases GastroPlus® X, The Next Generation PBPK/PBBM Modeling & Simulation SoftwareSimulations Plus, Inc. announced the release of GastroPlus® X. Branded as GPX™, this new platform represents the next generation of physiologically based pharmacokinetics/biopharmaceutics (PBPK/PBBM) modeling and simulation software. Utilizing proven top-rated science, advanced models, refined algorithms and integrated machine learning (ML) technology, GPX offers an entirely updated user experience with an intuitive interface, streamlined workflows, and faster processing. GPX is designed to be a comprehensive PBPK/PBBM modeling and simulation platform, allowing users to handle everything from early discovery high-throughput PK simulations and drug-drug interactions (DDIs) to population predictions and more all in the same place. Utilization of a single PBPK/PBBM platform, with reusable assets and templates, reduces the time spent on tedious tasks like model setup, importing and exporting data, and reformatting plotted modeling results. GPX offers flexible deployment options, allowing for both local installation and seamless integration with cloud environments, providing users with the freedom to choose the best setup for their needs.Seeking Alpha • May 14Simulations Plus: Reliance On Consulting And Acquisitions Creates DoubtsSummary Simulations Plus is benefiting from the growing use of computational tools in drug discovery, which would be boosted by the FDA Modernization Act 2.0. The biosimulation market is highly fragmented and underpenetrated, providing SLP with both organic and inorganic growth opportunities. While the company is operating in an attractive market and has a strong business, the company's valuation and growth prospects make the stock unappealing. Read the full article on Seeking AlphaRecent Insider Transactions Derivative • May 09lead Independent Director notifies of intention to sell stockDaniel Weiner intends to sell 3k shares in the next 90 days after lodging an Intent To Sell Form on the 7th of May. If the sale is conducted around the recent share price of US$48.21, it would amount to US$157k. Since September 2023, Daniel's direct individual holding has increased from 7.70k shares to 10.01k. Company insiders have collectively sold US$297k more than they bought, via options and on-market transactions in the last 12 months.Upcoming Dividend • Apr 22Upcoming dividend of US$0.06 per shareEligible shareholders must have bought the stock before 26 April 2024. Payment date: 06 May 2024. Payout ratio is a comfortable 46% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of American dividend payers (4.8%). Lower than average of industry peers (1.1%).Declared Dividend • Apr 07Second quarter dividend of US$0.06 announcedDividend of US$0.06 is the same as last year. Ex-date: 26th April 2024 Payment date: 6th May 2024 Dividend yield will be 0.5%, which is lower than the industry average of 0.9%. Payout Ratios Payout ratio: 46%. Cash payout ratio: 38%.株主還元SLPUS Healthcare ServicesUS 市場7D6.6%1.1%-0.3%1Y-54.4%-38.1%26.7%株主還元を見る業界別リターン: SLP過去 1 年間で-40.2 % の収益を上げたUS Healthcare Services業界を下回りました。リターン対市場: SLPは、過去 1 年間で23.3 % のリターンを上げたUS市場を下回りました。価格変動Is SLP's price volatile compared to industry and market?SLP volatilitySLP Average Weekly Movement7.0%Healthcare Services Industry Average Movement10.6%Market Average Movement7.2%10% most volatile stocks in US Market16.2%10% least volatile stocks in US Market3.2%安定した株価: SLP 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: SLPの 週次ボラティリティ ( 7% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1996213Shawn O'Connorwww.simulations-plus.comシミュレーション・プラス社は、人工知能や機械学習ベースの技術を活用したモデリングやシミュレーション、分子特性予測のための創薬・医薬品開発ソフトウェアを世界中で開発している。ソフトウェア事業とサービス事業を展開。同社は、ヒトおよび動物における吸収、生物薬剤学、薬物動態学、薬力学を予測するGastroPlus、DDDPlusおよびMembranePlusシミュレーション製品を提供している。また、DILIsym、NAFLDsym、ILDsym、IPFsym、RENAsym、MITOsym、OBESITYsym、Thales製品など、力学的・数学的モデルに基づく製品も提供している。また、分子構造を入力とし、その特性を予測する化学ベースのコンピュータプログラムである吸収・分布・代謝・排泄・毒性（ADMET）予測装置、MedChem Designer、さらに母集団解析、迅速な臨床試験データ解析、規制当局への申請を可能にするモデリングとシミュレーションのためのMonolixSuite製品も提供している。さらに、臨床薬理学に基づくコンサルティングサービスも提供しており、これには薬物動態・薬力学の母集団モデリング、曝露反応解析、臨床試験シミュレーション、データプログラミング、薬事申請をサポートするテクニカルライティングサービス、早期創薬サービスなどが含まれる。さらに、定量的システム薬理学やその他のモデリングシステムをサポートする、創造的で洞察力に富んだコンサルティングサービスも提供している。同社は製薬、バイオテクノロジー、農薬、化粧品、食品産業、学術機関、規制当局にサービスを提供している。Simulations Plus, Inc.は1996年に法人化され、ノースカロライナ州リサーチ・トライアングル・パークに本社を置いている。もっと見るSimulations Plus, Inc. 基礎のまとめSimulations Plus の収益と売上を時価総額と比較するとどうか。SLP 基礎統計学時価総額US$284.90m収益（TTM）-US$62.79m売上高(TTM)US$80.54m3.6xP/Sレシオ-4.7xPER（株価収益率SLP は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計SLP 損益計算書（TTM）収益US$80.54m売上原価US$30.63m売上総利益US$49.91mその他の費用US$112.70m収益-US$62.79m直近の収益報告Feb 28, 2026次回決算日該当なし一株当たり利益（EPS）-3.11グロス・マージン61.97%純利益率-77.96%有利子負債／自己資本比率0%SLP の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/20 05:08終値2026/05/20 00:00収益2026/02/28年間収益2025/08/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Simulations Plus, Inc. 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。11 アナリスト機関David LarsenBTIGDane LeoneCGS InternationalConstantine DavidesCitizens JMP Securities, LLC8 その他のアナリストを表示
ナラティブの更新 • Apr 29SLP: AI Regulatory Collaborations And Modest Growth Outlook Will Shape Balanced FutureAnalysts have maintained their $16.00 price target for Simulations Plus, noting that slightly adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E broadly offset one another in their updated models. What's in the News Announced a funded research collaboration with Lonza Group and the U.S. Food and Drug Administration (FDA) to develop a mechanistic framework for predicting in vivo performance of amorphous solid dispersion drug products, with the aim of supporting model informed drug development and potentially reducing reliance on some clinical bioequivalence studies (Key Developments).
お知らせ • Apr 24Simulations Plus, Inc. Announces Collaboration with Lonza Group Ag and U.S. Food and Drug Administration to Advance Predictive Frameworks for Complex Oral Drug ProductsSimulations Plus, Inc. had announced a funded research collaboration with Lonza Group AG and the U.S. Food and Drug Administration to develop and validate a mechanistic, predictive framework for assessing the in vivo performance of amorphous solid dispersion drug products. Mechanistic modeling approach and experimental integration designed to improve early risk identification, strengthen regulatory confidence, and expand AI-enabled workflows connecting data to decision-making. The collaboration evaluates whether advanced in vitro dissolution systems—particularly those incorporating dynamic gastrointestinal physiology—combined with mechanistic physiologically based biopharmaceutics modeling, can reliably predict key in vivo outcomes, including food effects and the impact of elevated gastric pH conditions. By establishing and validating these predictive capabilities, the collaboration aims to provide a scientific foundation for reducing reliance on certain clinical bioequivalence studies while maintaining the rigor and transparency required by regulators. Lonza will lead experimental work, including in vitro dissolution testing under fasted, fed, and elevated gastric pH conditions using advanced systems such as Controlled Transfer Dissolution, as well as the characterization and, where needed, manufacturing of amorphous solid dispersion formulation variants. Simulations Plus will lead the development and validation of in vitro–in vivo extrapolation frameworks using its DDDPlus® and GastroPlus® platforms, translating experimental data into predictions of in vivo pharmacokinetics and supporting virtual bioequivalence assessments. At the same time, it creates new opportunities to extend these capabilities into grounded AI-enabled workflow environments, where data, mechanistic models, and simulation outputs will be more directly connected. The Company will also contribute to interpretation within a regulatory context, ensuring alignment with evolving expectations for model-informed drug development. This work is supported in part through FDA funding and includes ongoing engagement with FDA scientists to directly align with regulatory priorities to advance model-informed drug development, modernize bioequivalence assessment for complex products, and reduce unnecessary reliance on human studies. By combining regulatory collaboration with open, non-proprietary data and validated methods based on real-world, FDA-approved amorphous solid dispersion products, the initiative is intended to inform future regulatory approaches and support broader adoption of science-based alternatives.
お知らせ • Apr 21Simulations Plus Inc Announces Completion of 2026 Spring School Global Training InitiativeSimulations Plus, Inc. announced the successful completion of its 2026 Spring School, a global training initiative designed to expand access to model-informed drug development (MIDD) and strengthen the scientific foundation of the industry’s future workforce. More than 1,400 scientists from industry, academia, and regulatory agencies from over 65 countries participated in the week-long program, reflecting the high demand for expert-led training as modeling and simulation increasingly become standard for drug development strategy, regulatory engagement, and clinical execution. Held from March 23 to 27, 2026, the Spring School program offered two tracks: GastroPlus Spring School: From PBPK Basics to Biopharmaceutics Applications, and MonolixSuite Spring School: High-Impact Pharmacometrics Case Studies. Both tracks included interactive lectures, hands-on exercises, and live Q&A sessions led by Simulations Plus experts. Simulations Plus has a long-standing commitment to education. In addition to its Spring School, the Company has previously offered Summer and Autumn Schools focused on PK/PD modeling. The most recent Autumn School was the first program to offer a second track focused on PBPK modeling. In addition to these programs, Simulations Plus is widely known for its University+ program, which provides free academic access to modeling and simulation software for thousands of students and educators worldwide. Together, these initiatives form a cornerstone of the Company’s global educational outreach—helping expand the adoption of model-informed approaches and strengthening the pipeline of scientists equipped to apply these methods across the drug development lifecycle.
Seeking Alpha • Apr 12Simulations Plus: Down Substantially, Not An Automatic BuySummary Simulations Plus trades at decade lows as investors question growth and AI disruption risks. SLP's Q2 sales grew 8% to $24.3M, but the full-year revenue outlook is flat to up 4%, with earnings guidance down. Valuation has compressed to 2.5x sales and ~20x realistic earnings, supported by a $42M net cash position. Despite improved margins and lower multiples, lack of growth and AI uncertainty keep me cautious on Simulations Plus. Read the full article on Seeking Alpha
ナラティブの更新 • Apr 12SLP: AI Collaborations With Pharma And Regulators Will Drive Long-Term UpsideAnalysts have reduced their price target for Simulations Plus from $20 to $16, citing updated assumptions that combine lower revenue growth expectations with a higher projected profit margin and a meaningfully lower future P/E multiple. What's in the News Simulations Plus announced collaboration programs with three large pharmaceutical companies to apply artificial intelligence within modeling workflows across the drug development lifecycle, using platforms such as GastroPlus, MonolixSuite, ADMET Predictor, and Thales (Key Developments).
Reported Earnings • Apr 10Second quarter 2026 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2026 results: EPS: US$0.23 (up from US$0.15 in 2Q 2025). Revenue: US$24.3m (up 8.3% from 2Q 2025). Net income: US$4.54m (up 48% from 2Q 2025). Profit margin: 19% (up from 14% in 2Q 2025). Revenue exceeded analyst estimates by 12%. Earnings per share (EPS) also surpassed analyst estimates by 11%. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 79 percentage points per year, which is a significant difference in performance.
ナラティブの更新 • Apr 29SLP: AI Regulatory Collaborations And Modest Growth Outlook Will Shape Balanced FutureAnalysts have maintained their $16.00 price target for Simulations Plus, noting that slightly adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E broadly offset one another in their updated models. What's in the News Announced a funded research collaboration with Lonza Group and the U.S. Food and Drug Administration (FDA) to develop a mechanistic framework for predicting in vivo performance of amorphous solid dispersion drug products, with the aim of supporting model informed drug development and potentially reducing reliance on some clinical bioequivalence studies (Key Developments).
お知らせ • Apr 24Simulations Plus, Inc. Announces Collaboration with Lonza Group Ag and U.S. Food and Drug Administration to Advance Predictive Frameworks for Complex Oral Drug ProductsSimulations Plus, Inc. had announced a funded research collaboration with Lonza Group AG and the U.S. Food and Drug Administration to develop and validate a mechanistic, predictive framework for assessing the in vivo performance of amorphous solid dispersion drug products. Mechanistic modeling approach and experimental integration designed to improve early risk identification, strengthen regulatory confidence, and expand AI-enabled workflows connecting data to decision-making. The collaboration evaluates whether advanced in vitro dissolution systems—particularly those incorporating dynamic gastrointestinal physiology—combined with mechanistic physiologically based biopharmaceutics modeling, can reliably predict key in vivo outcomes, including food effects and the impact of elevated gastric pH conditions. By establishing and validating these predictive capabilities, the collaboration aims to provide a scientific foundation for reducing reliance on certain clinical bioequivalence studies while maintaining the rigor and transparency required by regulators. Lonza will lead experimental work, including in vitro dissolution testing under fasted, fed, and elevated gastric pH conditions using advanced systems such as Controlled Transfer Dissolution, as well as the characterization and, where needed, manufacturing of amorphous solid dispersion formulation variants. Simulations Plus will lead the development and validation of in vitro–in vivo extrapolation frameworks using its DDDPlus® and GastroPlus® platforms, translating experimental data into predictions of in vivo pharmacokinetics and supporting virtual bioequivalence assessments. At the same time, it creates new opportunities to extend these capabilities into grounded AI-enabled workflow environments, where data, mechanistic models, and simulation outputs will be more directly connected. The Company will also contribute to interpretation within a regulatory context, ensuring alignment with evolving expectations for model-informed drug development. This work is supported in part through FDA funding and includes ongoing engagement with FDA scientists to directly align with regulatory priorities to advance model-informed drug development, modernize bioequivalence assessment for complex products, and reduce unnecessary reliance on human studies. By combining regulatory collaboration with open, non-proprietary data and validated methods based on real-world, FDA-approved amorphous solid dispersion products, the initiative is intended to inform future regulatory approaches and support broader adoption of science-based alternatives.
お知らせ • Apr 21Simulations Plus Inc Announces Completion of 2026 Spring School Global Training InitiativeSimulations Plus, Inc. announced the successful completion of its 2026 Spring School, a global training initiative designed to expand access to model-informed drug development (MIDD) and strengthen the scientific foundation of the industry’s future workforce. More than 1,400 scientists from industry, academia, and regulatory agencies from over 65 countries participated in the week-long program, reflecting the high demand for expert-led training as modeling and simulation increasingly become standard for drug development strategy, regulatory engagement, and clinical execution. Held from March 23 to 27, 2026, the Spring School program offered two tracks: GastroPlus Spring School: From PBPK Basics to Biopharmaceutics Applications, and MonolixSuite Spring School: High-Impact Pharmacometrics Case Studies. Both tracks included interactive lectures, hands-on exercises, and live Q&A sessions led by Simulations Plus experts. Simulations Plus has a long-standing commitment to education. In addition to its Spring School, the Company has previously offered Summer and Autumn Schools focused on PK/PD modeling. The most recent Autumn School was the first program to offer a second track focused on PBPK modeling. In addition to these programs, Simulations Plus is widely known for its University+ program, which provides free academic access to modeling and simulation software for thousands of students and educators worldwide. Together, these initiatives form a cornerstone of the Company’s global educational outreach—helping expand the adoption of model-informed approaches and strengthening the pipeline of scientists equipped to apply these methods across the drug development lifecycle.
Seeking Alpha • Apr 12Simulations Plus: Down Substantially, Not An Automatic BuySummary Simulations Plus trades at decade lows as investors question growth and AI disruption risks. SLP's Q2 sales grew 8% to $24.3M, but the full-year revenue outlook is flat to up 4%, with earnings guidance down. Valuation has compressed to 2.5x sales and ~20x realistic earnings, supported by a $42M net cash position. Despite improved margins and lower multiples, lack of growth and AI uncertainty keep me cautious on Simulations Plus. Read the full article on Seeking Alpha
ナラティブの更新 • Apr 12SLP: AI Collaborations With Pharma And Regulators Will Drive Long-Term UpsideAnalysts have reduced their price target for Simulations Plus from $20 to $16, citing updated assumptions that combine lower revenue growth expectations with a higher projected profit margin and a meaningfully lower future P/E multiple. What's in the News Simulations Plus announced collaboration programs with three large pharmaceutical companies to apply artificial intelligence within modeling workflows across the drug development lifecycle, using platforms such as GastroPlus, MonolixSuite, ADMET Predictor, and Thales (Key Developments).
Reported Earnings • Apr 10Second quarter 2026 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2026 results: EPS: US$0.23 (up from US$0.15 in 2Q 2025). Revenue: US$24.3m (up 8.3% from 2Q 2025). Net income: US$4.54m (up 48% from 2Q 2025). Profit margin: 19% (up from 14% in 2Q 2025). Revenue exceeded analyst estimates by 12%. Earnings per share (EPS) also surpassed analyst estimates by 11%. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 79 percentage points per year, which is a significant difference in performance.
お知らせ • Mar 27Simulations Plus, Inc. to Report Q2, 2026 Results on Apr 09, 2026Simulations Plus, Inc. announced that they will report Q2, 2026 results After-Market on Apr 09, 2026
分析記事 • Feb 08Simulations Plus, Inc.'s (NASDAQ:SLP) 26% Share Price Plunge Could Signal Some RiskSimulations Plus, Inc. ( NASDAQ:SLP ) shareholders won't be pleased to see that the share price has had a very rough...
分析記事 • Feb 06Is There An Opportunity With Simulations Plus, Inc.'s (NASDAQ:SLP) 38% Undervaluation?Key Insights Using the 2 Stage Free Cash Flow to Equity, Simulations Plus fair value estimate is US$22.72 Simulations...
Buy Or Sell Opportunity • Jan 30Now 24% undervalued after recent price dropOver the last 90 days, the stock has fallen 1.8% to US$16.87. The fair value is estimated to be US$22.06, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Meanwhile, the company became loss making.
Price Target Changed • Jan 22Price target increased by 10% to US$24.67Up from US$22.33, the current price target is an average from 3 analysts. New target price is 19% above last closing price of US$20.74. Stock is down 38% over the past year. The company is forecast to post earnings per share of US$0.54 next year compared to a net loss per share of US$3.22 last year.
Reported Earnings • Jan 09First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2026 results: EPS: US$0.034 (up from US$0.01 in 1Q 2025). Revenue: US$18.4m (down 2.7% from 1Q 2025). Net income: US$676.0k (up 228% from 1Q 2025). Profit margin: 3.7% (up from 1.1% in 1Q 2025). Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) missed analyst estimates by 63%. Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 90 percentage points per year, which is a significant difference in performance.
お知らせ • Jan 09Simulations Plus, Inc. Reaffirms Earnings Guidance for Fiscal 2026Simulations Plus, Inc. reaffirmed earnings guidance for Fiscal 2026. For the period, the company expects Revenue to be in the range of $79 Million to $82 Million.
ナラティブの更新 • Jan 07SLP: Reaffirmed Guidance And AI Roadmap Will Support Further UpsideAnalysts have trimmed their price target on Simulations Plus to about US$22.33 per share, reflecting a slightly higher discount rate and P/E assumptions that point to a more cautious stance on profitability. What's in the News Simulations Plus plans an Analyst and Investor Day focused on presenting its new product vision and AI solutions, highlighting where management is aiming future product development (Key Developments).
お知らせ • Dec 30Simulations Plus, Inc., Annual General Meeting, Feb 12, 2026Simulations Plus, Inc., Annual General Meeting, Feb 12, 2026.
お知らせ • Dec 17Simulations Plus, Inc. to Report Q1, 2026 Results on Jan 08, 2026Simulations Plus, Inc. announced that they will report Q1, 2026 results After-Market on Jan 08, 2026
ナラティブの更新 • Dec 14SLP: Reinforced Revenue Outlook Will Drive Upside From Current LevelsAnalysts have modestly reduced their price target on Simulations Plus to approximately 22.33 dollars from 23 dollars. This reflects a recalibration of valuation multiples, even as they acknowledge stronger revenue growth and a significantly improved profit margin outlook.
Reported Earnings • Dec 03Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: US$3.22 loss per share (down from US$0.50 profit in FY 2024). Revenue: US$79.2m (up 13% from FY 2024). Net loss: US$64.7m (down US$74.7m from profit in FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 1.1%. Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 82 percentage points per year, which is a significant difference in performance.
お知らせ • Dec 02Simulations Plus, Inc. Reaffirms Revenue Guidance for Fiscal 2026Simulations Plus, Inc. reaffirmed revenue guidance for fiscal 2026. For the year, the company expects revenue of $79 million to $82 million.
ナラティブの更新 • Nov 29SLP: Revenue Guidance Will Support Renewed Upside Despite Index ExclusionsAnalysts have maintained their price target for Simulations Plus at $23.00. They cited stable assumptions for revenue growth, profit margins, and valuation multiples in their latest assessment.
ナラティブの更新 • Nov 15SLP: Revenue Forecasts Will Drive Potential Gains Despite Index RemovalsAnalysts have modestly adjusted their price target for Simulations Plus from $23.00 to $23.00. They cite subtle changes in assumptions around discount rate and profit margins, while maintaining steady core growth expectations.
ナラティブの更新 • Nov 01SLP: Upcoming Earnings Guidance And Index Changes Will Drive Renewed OptimismAnalysts have adjusted their price target for Simulations Plus to $23.00. This reflects slight updates in their financial forecasts and expectations for future growth and profitability.
分析記事 • Oct 28Simulations Plus, Inc. (NASDAQ:SLP) Shares Could Be 44% Below Their Intrinsic Value EstimateKey Insights Using the 2 Stage Free Cash Flow to Equity, Simulations Plus fair value estimate is US$32.42 Simulations...
お知らせ • Oct 22+ 1 more updateSimulations Plus, Inc. to Report Q4, 2025 Results on Dec 01, 2025Simulations Plus, Inc. announced that they will report Q4, 2025 results at 4:00 PM, US Eastern Standard Time on Dec 01, 2025
ナラティブの更新 • Oct 18Software Licensing Expansion And Integrated Services Will Ensure Future SuccessAnalysts have maintained the fair value estimate for Simulations Plus at $23.00. This reflects stable long-term growth expectations, even with only slight adjustments to underlying assumptions.
ナラティブの更新 • Oct 03Software Licensing Expansion And Integrated Services Will Ensure Future SuccessAnalysts have revised their price target for Simulations Plus downward from $25.33 to $23.00, citing lower projected revenue growth and profit margins as key factors in their updated outlook. What's in the News Simulations Plus was removed from the S&P Composite 1500, S&P 1000, S&P 600, and S&P 600 Health Care indices (Key Developments).
Recent Insider Transactions Derivative • Oct 02Director notifies of intention to sell stockWalter Woltosz intends to sell 20k shares in the next 90 days after lodging an Intent To Sell Form on the 1st of October. If the sale is conducted around the recent share price of US$15.07, it would amount to US$301k. Since December 2024, Walter's direct individual holding has decreased from 3.44m shares to 3.31m. There have been no trades via on-market transactions or options from company insiders in the last 12 months.
分析記事 • Jul 31Some Simulations Plus, Inc. (NASDAQ:SLP) Shareholders Look For Exit As Shares Take 25% PoundingUnfortunately for some shareholders, the Simulations Plus, Inc. ( NASDAQ:SLP ) share price has dived 25% in the last...
お知らせ • Jul 29Simulations Plus, Inc. and Institute of Medical Biology of the Polish Academy of Sciences Partnership Announces Results in Validation of ADMET Predictor Models with Enhanced AI Drug DesignSimulations Plus, Inc. announced that experimental results of its artificial intelligence-driven drug design (AIDD) collaboration with the Institute of Medical Biology of the Polish Academy of Sciences (IMB PAS) have been published in the American Chemical Society (ACS) Medical Chemical Letters. Simulations Plus and IMB PAS launched their collaboration in 2023 to use the AIDD module in ADMET Predictor®? to design novel RORg/RORgT ligands, molecules that impact gene expression related to inflammation and immune responses. Within three months, the two teams had developed models to predict RORg/RORg T ligand potency, designed potential ligands simultaneously optimized for potency, in vivo absorption, synthesizability, and ADMET risk, synthesized compounds, and completed initial in vitro potency and toxicity testing. The recently published results show that the vast majority of compounds tested had strong potency for the target that was close to or better than the values predicted by ADMET Predictor.
Reported Earnings • Jul 15Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2025 results: US$3.35 loss per share (down from US$0.16 profit in 3Q 2024). Revenue: US$20.4m (up 9.8% from 3Q 2024). Net loss: US$67.3m (down US$70.5m from profit in 3Q 2024). Revenue exceeded analyst estimates by 4.0%. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 9.8% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 35 percentage points per year, which is a significant difference in performance.
お知らせ • Jul 15Simulations Plus, Inc. Updates Earnings Guidance for the Fiscal Year 2025Simulations Plus, Inc. updated earnings guidance for the fiscal year 2025. For the year, the company expects revenue to be between $76 million to $80 million. Revenue growth to be between 9% to 14%.
Major Estimate Revision • Jul 08Consensus EPS estimates fall by 16%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from US$81.7m to US$79.9m. EPS estimate also fell from US$0.363 per share to US$0.307 per share. Net income forecast to grow 39% next year vs 25% growth forecast for Healthcare Services industry in the US. Consensus price target down from US$36.25 to US$32.25. Share price fell 4.4% to US$17.51 over the past week.
Recent Insider Transactions Derivative • Jul 02Director notifies of intention to sell stockWalter Woltosz intends to sell 60k shares in the next 90 days after lodging an Intent To Sell Form on the 1st of July. If the sale is conducted around the recent share price of US$17.45, it would amount to US$1.0m. Since September 2024, Walter's direct individual holding has decreased from 3.50m shares to 3.32m. There has only been one transaction (US$22k purchase) from insiders over the last 12 months.
Valuation Update With 7 Day Price Move • Jun 17Investor sentiment deteriorates as stock falls 33%After last week's 33% share price decline to US$18.32, the stock trades at a forward P/E ratio of 35x. Average trailing P/E is 56x in the Healthcare Services industry in the US. Total loss to shareholders of 58% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$30.51 per share.
Major Estimate Revision • Jun 13Consensus EPS estimates fall by 20%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from US$90.3m to US$85.8m. EPS estimate also fell from US$0.555 per share to US$0.443 per share. Net income forecast to grow 73% next year vs 25% growth forecast for Healthcare Services industry in the US. Consensus price target down from US$42.00 to US$36.25. Share price fell 31% to US$19.07 over the past week.
分析記事 • Jun 13Simulations Plus, Inc.'s (NASDAQ:SLP) Stock Retreats 36% But Earnings Haven't Escaped The Attention Of InvestorsSimulations Plus, Inc. ( NASDAQ:SLP ) shares have had a horrible month, losing 36% after a relatively good period...
New Risk • Jun 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Profit margins are more than 30% lower than last year (9.2% net profit margin).
Buy Or Sell Opportunity • Jun 12Now 34% undervalued after recent price dropOver the last 90 days, the stock has fallen 23% to US$20.05. The fair value is estimated to be US$30.41, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has declined by 12%. Revenue is forecast to grow by 24% in 2 years. Earnings are forecast to grow by 120% in the next 2 years.
お知らせ • Jun 12+ 1 more updateSimulations Plus, Inc. Provides Revenue Guidance for the Third Quarter and Full Year of Fiscal 2025Simulations Plus, Inc. provided revenue guidance for the third quarter and Full year of fiscal 2025. The Company expected to report third quarter fiscal 2025 revenue in the range of between $19 million and $20 million. Full year fiscal 2025 revenue is expected to range between $76 million and $80 million.
お知らせ • Jun 05Simulations Plus, Inc. Releases ADMET Predictor 13Simulations Plus, Inc. announced the release of ADMET Predictor 13, its machine learning (ML) modeling platform for the design, optimization, and selection of new molecules during various stages of drug discovery. ADMET Predictor 13 features advancements in three main areas: First-to-invent advantage: clients can harness enhanced high-throughput PBPK (HT-PBPK) simulations--powered by GastroPlus®?--combined with the upgraded AI-driven drug design (AIDD) engine to enable faster, smarter decision-making at the intersection of chemistry and pharmacokinetics. Elevated predictive power: ADMET Predictor 13 offers an expanded suite of next-gen ADMET models, built with updated AI science and premium datasets, which boost accuracy across key endpoints and reinforce scientific rigor and validation. Enterprise-ready automation: with extended APIs, Python scripting support, and IT-friendly deployment capabilities, ADMET Predictor 13 delivers the automation and scalability required by today's data-centric R&D teams.
Valuation Update With 7 Day Price Move • Jun 02Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to US$26.37, the stock trades at a forward P/E ratio of 41x. Average trailing P/E is 56x in the Healthcare Services industry in the US. Total loss to shareholders of 46% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$40.28 per share.
Buy Or Sell Opportunity • May 21Now 21% undervaluedThe stock has been flat over the last 90 days, currently trading at US$31.70. The fair value is estimated to be US$40.00, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has declined by 12%. Revenue is forecast to grow by 36% in 2 years. Earnings are forecast to grow by 137% in the next 2 years.
お知らせ • May 15Simulations Plus, Inc. Releases DILIsym 11Simulations Plus, Inc. announced the release of DILIsym 11, the latest version of its quantitative systems toxicology (QST) platform. DILIsym is a software platform designed to predict potential DILI hazards and provide insight into the mechanisms responsible for observed DILI responses. It is the most widely used QST modeling software for DILI prediction and is utilized as a source of QST modeling-based data assessed by the U.S. Food and Drug Administration's (FDA) DILIsym team. DILIsym 11 offers new pediatric representation for exploratory predictions regarding liver safety to children, and a new T-cell model that allows for better understanding of putative contributions of CD8+ T-cell mediated hepatocellular injury. It also includes improved representation of bile acid and cholestatic liver injury, updated antioxidant adaptation mechanisms, and more.
分析記事 • May 07Are Investors Undervaluing Simulations Plus, Inc. (NASDAQ:SLP) By 28%?Key Insights The projected fair value for Simulations Plus is US$40.15 based on 2 Stage Free Cash Flow to Equity...
Buy Or Sell Opportunity • May 06Now 28% undervalued after recent price dropOver the last 90 days, the stock has fallen 20% to US$29.01. The fair value is estimated to be US$40.17, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has declined by 12%. Revenue is forecast to grow by 36% in 2 years. Earnings are forecast to grow by 137% in the next 2 years.
Price Target Changed • Apr 25Price target increased by 9.4% to US$46.60Up from US$42.60, the current price target is an average from 5 analysts. New target price is 31% above last closing price of US$35.50. Stock is down 21% over the past year. The company is forecast to post earnings per share of US$0.56 for next year compared to US$0.50 last year.
お知らせ • Apr 21Simulations Plus, Inc. Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety StudiesSimulations Plus, Inc. announced its support of the U.S. Food and Drug Administration's (FDA) recently announced roadmap for reducing animal testing through the use of new approach methodologies (NAMs). Simulations Plus has long provided the software and consulting service expertise to successfully implement the FDA roadmap. The new FDA roadmap outlines a path to incorporate methodologies such as organ-on-a-chip, advanced in vitro assays, and computational modeling in preclinical safety studies, with an initial focus on monoclonal antibody (mAb) testing. Simulations Plus software platforms are utilized by mAb-focused researchers for key decision-making, including: GastroPlus accelerates the assessment of dosing and delivery strategies needed to achieve desired clinical endpoints, enabling researchers to reduce--and in some cases, eliminate--animal testing during non-clinical development. In addition, Simulations Plus' software and consulting services are regularly relied upon by researchers to predict efficacy and safety of compounds and prioritize top drug candidates for further development--contributing to a reduction in animal testing and more focused clinical trials. Simulations Plus' PBPK services team delivers high-value scientific expertise to help clients replace or reduce animal testing by developing and validating predictive PBPK models that integrate standard in vitro and in silico data to simulate human and animal pharmacometrics. Many organizations will need more than new modeling tools and in vitro systems. To follow the FDA roadmap, companies not currently incorporating NAMs into their development processes and timelines may also require consulting services, regulatory guidance and training on new tools.
Seeking Alpha • Apr 16Simulations Plus: Benefiting From FDA Modernization And AISummary Simulations Plus, Inc. offers AI-based software tools for drug discovery and optimization, significantly reducing R&D time and costs for pharmaceutical research. SLP's diverse software portfolio, including GastroPlus and ADMET Predictor, and consulting services position it as a comprehensive partner in biotech development. Favorable regulatory changes by the FDA towards AI and non-animal testing methods boost SLP's market potential, despite its current high valuation. SLP's long-term outlook remains strong due to its innovative approach and the growing adoption of AI in drug testing, making it a "Buy" for long-term investors. Read the full article on Seeking Alpha
分析記事 • Apr 13Simulations Plus, Inc.'s (NASDAQ:SLP) 25% Jump Shows Its Popularity With InvestorsSimulations Plus, Inc. ( NASDAQ:SLP ) shareholders would be excited to see that the share price has had a great month...
Reported Earnings • Apr 04Second quarter 2025 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2025 results: EPS: US$0.15 (down from US$0.20 in 2Q 2024). Revenue: US$22.4m (up 23% from 2Q 2024). Net income: US$3.07m (down 24% from 2Q 2024). Profit margin: 14% (down from 22% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.3%. Earnings per share (EPS) also surpassed analyst estimates by 22%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings.
お知らせ • Apr 04Simulations Plus, Inc. Provides Earnings Guidance for the Year 2025Simulations Plus, Inc. provided earnings guidance for the year 2025. For the year, the company expects revenue of $90 million to $93 million. Revenue growth of 28% to 33%.
お知らせ • Mar 20Simulations Plus, Inc. to Report Q2, 2025 Results on Apr 03, 2025Simulations Plus, Inc. announced that they will report Q2, 2025 results After-Market on Apr 03, 2025
Valuation Update With 7 Day Price Move • Feb 25Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to US$30.50, the stock trades at a forward P/E ratio of 59x. Average trailing P/E is 61x in the Healthcare Services industry in North America. Total loss to shareholders of 23% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$41.85 per share.
分析記事 • Feb 08Why Investors Shouldn't Be Surprised By Simulations Plus, Inc.'s (NASDAQ:SLP) 29% Share Price SurgeSimulations Plus, Inc. ( NASDAQ:SLP ) shareholders would be excited to see that the share price has had a great month...
Buy Or Sell Opportunity • Feb 06Now 21% undervaluedOver the last 90 days, the stock has risen 16% to US$35.58. The fair value is estimated to be US$44.98, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has declined by 7.1%. Revenue is forecast to grow by 41% in 2 years. Earnings are forecast to grow by 102% in the next 2 years.
Major Estimate Revision • Jan 15Consensus EPS estimates fall by 38%The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate fell from US$0.763 to US$0.475 per share. Revenue forecast steady at US$90.4m. Net income forecast to grow 38% next year vs 19% growth forecast for Healthcare Services industry in the US. Consensus price target of US$49.00 unchanged from last update. Share price was steady at US$28.76 over the past week.
Reported Earnings • Jan 08First quarter 2025 earnings: EPS misses analyst expectationsFirst quarter 2025 results: EPS: US$0.01 (down from US$0.098 in 1Q 2024). Revenue: US$18.9m (up 31% from 1Q 2024). Net income: US$206.0k (down 89% from 1Q 2024). Profit margin: 1.1% (down from 13% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 86%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 9.4% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 16% per year, which means it is performing significantly worse than earnings.
分析記事 • Jan 08Capital Allocation Trends At Simulations Plus (NASDAQ:SLP) Aren't IdealIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. One common...
お知らせ • Jan 08Simulations Plus, Inc. Provides Earnings Guidance for the Fiscal 2025Simulations Plus, Inc. provided earnings guidance for the fiscal 2025. For the period, the company expects Revenue to be in the range of $90 million to $93 million.
Board Change • Jan 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 2 highly experienced directors. Independent Director Sharlene Evans was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Dec 24Simulations Plus, Inc., Annual General Meeting, Feb 13, 2025Simulations Plus, Inc., Annual General Meeting, Feb 13, 2025.
お知らせ • Dec 20Simulations Plus, Inc. to Report Q1, 2025 Results on Jan 07, 2025Simulations Plus, Inc. announced that they will report Q1, 2025 results After-Market on Jan 07, 2025
Valuation Update With 7 Day Price Move • Nov 25Investor sentiment improves as stock rises 16%After last week's 16% share price gain to US$32.74, the stock trades at a forward P/E ratio of 43x. Average trailing P/E is 57x in the Healthcare Services industry in North America. Total loss to shareholders of 30% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$47.71 per share.
お知らせ • Nov 13Simulations Plus, Inc. and University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting InjectablesSimulations Plus, Inc. announced that it has been awarded a newly funded grant from the U.S. Food and Drug Administration (FDA) to use physiologically based pharmacokinetic (PBPK) approaches in GastroPlus to build and validate mechanistic in vitro-in vivo correlations (IVIVCs) for long-acting injectable (LAI) technologies through a joint proposal with the University of Connecticut’s School of Pharmacy, Department of Pharmaceutical Sciences. This project aims to use the GastroPlus PBPK platform to investigate the intricate relationship between LAI formulation critical quality attributes (CQAs) and physiological factors at the injection site to accurately predict in vivo drug release and absorption. Dr. Diane Burgess, Board of Trustees Distinguished Professor of Pharmaceutics and Pfizer Distinguished Endowed Chair of Pharmaceutical Technology at the University of Connecticut and her lab will generate in vitro and in vivo data for marketed LAI suspension products using novel discriminatory systems. The scientific team at Simulations Plus will use this data, along with additional inputs from research collaborators, to develop PBPK models and apply them to validate mechanistic IVIVCs. This effort is expected to lay the groundwork for a practical alternative to in vivo studies in establishing bioequivalence (BE) for additional LAI product technologies. FDA scientific and program staff will actively collaborate with the University of Connecticut, Simulations Plus, and select industry partners. Dr. Silva Ryan, with assistance from scientists at Simulations Plus, will coordinate the contract’s modeling and simulation activities. Funding for this collaboration is made possible by the FDA through grant award 1U01FD008304-01. Views expressed in this press release do not necessarily reflect the official policies of the Department of Health and Human Services; nor does any mention of trade names, commercial practices, or organizations imply endorsement by the United States Government.
分析記事 • Nov 07We Think Simulations Plus' (NASDAQ:SLP) Healthy Earnings Might Be ConservativeDespite posting healthy earnings, Simulations Plus, Inc.'s ( NASDAQ:SLP ) stock has been quite weak. Along with the...
Valuation Update With 7 Day Price Move • Oct 30Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to US$28.68, the stock trades at a forward P/E ratio of 45x. Average trailing P/E is 49x in the Healthcare Services industry in the US. Total loss to shareholders of 45% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$47.73 per share.
新しいナラティブ • Oct 27Biosimulation Innovations And Tactical Acquisitions To Boost Drug Development Growth Integration and expansion into new markets drive revenue growth and improved profitability through increased efficiencies and enhanced offerings.
Price Target Changed • Oct 27Price target decreased by 7.5% to US$52.75Down from US$57.00, the current price target is an average from 4 analysts. New target price is 72% above last closing price of US$30.68. Stock is down 9.7% over the past year. The company is forecast to post earnings per share of US$0.64 for next year compared to US$0.50 last year.
Reported Earnings • Oct 24Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2024 results: EPS: US$0.50. Revenue: US$70.0m (up 18% from FY 2023). Net income: US$9.95m (flat on FY 2023). Profit margin: 14% (down from 17% in FY 2023). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.5%. Earnings per share (EPS) exceeded analyst estimates by 4.3%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Healthcare Services industry in the US.
お知らせ • Oct 24Simulations Plus, Inc. Provides Earnings Guidance for Fiscal Year 2025Simulations Plus, Inc. provided earnings guidance for Fiscal year 2025. For the period, the company expects Revenue to be in the range of $90 million to $93 million.
お知らせ • Oct 10Simulations Plus, Inc. to Report Q4, 2024 Results on Oct 23, 2024Simulations Plus, Inc. announced that they will report Q4, 2024 results After-Market on Oct 23, 2024
お知らせ • Oct 08Simulations Plus and the University of Southern California Secure NIH Grant to Develop New AI Drug Discovery OfferingsSimulations Plus, Inc. announced the award of a new research grant from the National Institutes of Health (NIH), secured in partnership with the University of Southern California (USC) Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences. The grant will be used to evaluate novel computational methods that account for water-ligand interactions in drug discovery and that integrate with the Artificial Intelligence-driven Drug Design (AIDD) module in ADMET Predictor to offer a first-of-its-kind ligand-based virtual screening (LBVS) solution for pharmaceutical companies. For this award, Dr. Ian Haworth, Associate Professor and Vice Chair of Pharmacology and Pharmaceutical Sciences at the USC Mann School, and his lab will apply their previously developed algorithm (WATGEN) for the prediction of water positions in the unbound protein and protein-ligand complex. With support from the data scientists and software engineers at Simulations Plus, they will apply machine learning (ML) approaches to predict the pharmacophore features that will be used in ADMET Predictor’s proprietary 3D shape and feature matching algorithm. The team at Simulations Plus will productize the updated methods into the ADMET Predictor platform and validate it by designing drugs against defined targets using the AIDD module. Selected compounds will be synthesized and tested experimentally to highlight the technology’s applications.
お知らせ • Aug 23Simulations Plus, Inc. Announces Executive Changes, Effective August 30, 2024Simulations Plus, Inc. announced the optimization of its business unit and leadership structure to support future growth following the company’s recent acquisitions. These actions will be effective August 30, 2024. The company announced the following leadership promotions and transitions: Steven Changwill be promoted to President, Quantitative Systems Pharmacology. Mr. Chang joined Simulations Plus in June 2023 with the acquisition of Immunetrics and served as its President and Chief Executive Officer since 2002. He is a successful technology entrepreneur with more than three decades of experience in identifying emerging market needs and combining state-of-the-art technologies and resources to meet those needs. Jenna Rousewill be promoted to President of the newly formed Adaptive Learning & Insights business unit. Ms. Rouse joined Simulations Plus with the acquisition of Pro-ficiency where, as Chief Markets Officer, Clinical, she spent five years driving the growth and engagement with the organization’s simulation-enabled training solutions for clinical trial optimization, competency development, and continuing medical education. Prior to joining Pro-ficiency, she spent 25 years in workforce development in regulated industries, with over 15 years dedicated to professional development and adult learning in clinical trials. Murry Alper will be promoted to President of the newly formed Medical Communications business unit. Mr. Alper joined Simulations Plus with the acquisition of Pro-ficiency. Mr. Alper brings almost 30 years of experience in the life sciences industry, with experience at both major developers, as well as on the agency side. Mr. Alper founded Caravel Group in 2006 after a decade in marketing and sales roles at Bristol-Myers Squibb and Genentech. He has co-founded multiple medical communications agencies and was Managing Partner of Compass Group Partners upon its purchase by Pro-ficiency in June of 2023. Sandra Suarez-Sharp, Ph.D., will transition to President, Regulatory Strategies Center of Excellence. Dr. Suarez-Sharp joined Simulations Plus in 2020 and has been instrumental in facilitating the Company’s regulatory support to clients. Prior to joining Simulations Plus, Dr. Suarez-Sharp had a long and successful career at the Food and Drug Administration, including roles in biopharmaceutics, bioequivalence, and clinical pharmacology. In her new role, she is responsible for expanding the Regulatory Strategies Center of Excellence to accelerate cross-selling opportunities driven by the rapidly growing demand for biosimulation solutions. The company also announced the following departures: Brett Howell, Ph.D., President, Quantitative Systems Pharmacology and Michael Raymer, President, Clinical Simulations & Medical Communications will be leaving Simulations Plus after assisting with the transition process.
Seeking Alpha • Aug 22Simulations Plus: Declining Margins Are A ProblemSummary Simulations Plus growth is steady, but its margins continue to decline. This has been problematic due to the company's high valuation. Simulations Plus has suggested that the demand environment is improving, but its guidance implies a meaningful deceleration in organic growth. Simulations Plus likely needs to maintain its growth rate while improving margins before its share price moves higher. The decision to cut the company's dividend suggests that an improvement in margins and cash flows could be some way off. Read the full article on Seeking Alpha
Buy Or Sell Opportunity • Aug 02Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 17% to US$38.60. The fair value is estimated to be US$49.11, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has declined by 3.6%. Revenue is forecast to grow by 53% in 2 years. Earnings are forecast to grow by 51% in the next 2 years.
お知らせ • Aug 02Simulations Plus, Inc. Releases the latest version of its quantitative systems toxicology (QST) platform, DILIsym version XSimulations Plus, Inc. has released the latest version of its quantitative systems toxicology (QST) platform, DILIsym version X. Branded as DSX™?, the software is designed to support key drug development decisions by predicting potential drug-induced liver injury (DILI) risks. These predictions can guide go/no-go decisions, or the need to modify doses, which are vital to avoiding costly failed clinical trials. DSX offers a completely redesigned interface, tested by clients and consultants, that includes both command line and graphical interface options as well as a licensing option that enables scale-up on local or cloud cluster configurations. Four new exemplar compounds are included in this version of the software, as well as two new simulation populations that include variability in susceptibility to liver injury and biomarker-related parameters (ALT and bilirubin).
Upcoming Dividend • Jul 22Upcoming dividend of US$0.06 per shareEligible shareholders must have bought the stock before 29 July 2024. Payment date: 05 August 2024. The company last paid an ordinary dividend in November 2013. The average dividend yield among industry peers is 1.1%.
Seeking Alpha • Jul 10Simulations Plus: Steady Growth, But What About The Margins?Summary Simulations Plus, Inc. has seen stagnant stock trading despite impressive growth in the biosimulation market. Recent margin pressure and M&A activity raise concerns about management's ability to deliver. Acquisition of Pro-ficiency Holdings doubles the addressable market, but uncertainty remains about growth and margins amidst a demanding valuation. Read the full article on Seeking Alpha
Major Estimate Revision • Jul 09Consensus EPS estimates fall by 14%The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate fell from US$0.547 to US$0.47 per share. Revenue forecast steady at US$71.2m. Net income forecast to grow 28% next year vs 25% growth forecast for Healthcare Services industry in the US. Consensus price target of US$60.33 unchanged from last update. Share price fell 16% to US$39.57 over the past week.
Declared Dividend • Jul 05Third quarter dividend of US$0.06 announcedShareholders will receive a dividend of US$0.06. Ex-date: 29th July 2024 Payment date: 5th August 2024 Dividend yield will be 0.6%, which is lower than the industry average of 0.9%.
Reported Earnings • Jul 05Third quarter 2024 earnings: EPS in line with analyst expectations despite revenue beatThird quarter 2024 results: EPS: US$0.16 (down from US$0.20 in 3Q 2023). Revenue: US$18.5m (up 14% from 3Q 2023). Net income: US$3.14m (down 22% from 3Q 2023). Profit margin: 17% (down from 25% in 3Q 2023). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Healthcare Services industry in the US. Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has fallen by 9% per year.
お知らせ • Jul 03+ 1 more updateSimulations Plus, Inc. Updates Earnings Guidance for the Fiscal 2024Simulations Plus, Inc. updated earnings guidance for the fiscal 2024. The company maintained revenue of $69 million to $72 million. Diluted EPS of $0.46 - $0.48.
Buy Or Sell Opportunity • Jul 01Now 12% overvalued after recent price riseOver the last 90 days, the stock has risen 20% to US$46.18. The fair value is estimated to be US$41.15, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has declined by 2.8%. Revenue is forecast to grow by 53% in 2 years. Earnings are forecast to grow by 69% in the next 2 years.
Buy Or Sell Opportunity • Jun 21Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 12% to US$48.15. The fair value is estimated to be US$39.87, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has declined by 2.8%. Revenue is forecast to grow by 52% in 2 years. Earnings are forecast to grow by 69% in the next 2 years.
お知らせ • Jun 19Simulations Plus, Inc. to Report Q3, 2024 Results on Jul 02, 2024Simulations Plus, Inc. announced that they will report Q3, 2024 results After-Market on Jul 02, 2024
Major Estimate Revision • Jun 18Consensus EPS estimates fall by 17%, revenue upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from US$68.1m to US$70.8m. EPS estimate fell from US$0.657 to US$0.547 per share. Net income forecast to grow 29% next year vs 25% growth forecast for Healthcare Services industry in the US. Consensus price target up from US$55.33 to US$60.33. Share price rose 2.5% to US$47.21 over the past week.
Price Target Changed • Jun 13Price target increased by 12% to US$60.33Up from US$53.67, the current price target is an average from 3 analysts. New target price is 24% above last closing price of US$48.62. Stock is up 3.4% over the past year. The company is forecast to post earnings per share of US$0.59 for next year compared to US$0.50 last year.
お知らせ • Jun 13Simulations Plus, Inc. (NasdaqGS:SLP) acquired Pro-ficiency, LLC from NovaQuest Capital Management, L.L.C., QHP Capital, L.P. and Pro-ficiency’s minority shareholders for approximately $100 million.Simulations Plus, Inc. (NasdaqGS:SLP) acquired Pro-ficiency, LLC from NovaQuest Capital Management, L.L.C., QHP Capital, L.P. and Pro-ficiency’s minority shareholders for approximately $100 million on June 12, 2024. The transaction is expected to be accretive to fiscal 2025 EPS. The transaction is being funded from existing cash and investment resources. With approximately $119 million in cash and investments available, this acquisition allows Simulations to utilize the capital from August 2020 follow-on public offering. Procopio acted as legal counsel for Simulations Plus and Wyrick Robbins acted as legal counsel for Pro-ficiency and the sellers of Pro-ficiency. Simulations Plus, Inc. (NasdaqGS:SLP) completed the acquisition of Pro-ficiency, LLC from NovaQuest Capital Management, L.L.C., QHP Capital, L.P. and Pro-ficiency’s minority shareholders on June 12, 2024.
お知らせ • May 16Simulations Plus Releases GastroPlus® X, The Next Generation PBPK/PBBM Modeling & Simulation SoftwareSimulations Plus, Inc. announced the release of GastroPlus® X. Branded as GPX™, this new platform represents the next generation of physiologically based pharmacokinetics/biopharmaceutics (PBPK/PBBM) modeling and simulation software. Utilizing proven top-rated science, advanced models, refined algorithms and integrated machine learning (ML) technology, GPX offers an entirely updated user experience with an intuitive interface, streamlined workflows, and faster processing. GPX is designed to be a comprehensive PBPK/PBBM modeling and simulation platform, allowing users to handle everything from early discovery high-throughput PK simulations and drug-drug interactions (DDIs) to population predictions and more all in the same place. Utilization of a single PBPK/PBBM platform, with reusable assets and templates, reduces the time spent on tedious tasks like model setup, importing and exporting data, and reformatting plotted modeling results. GPX offers flexible deployment options, allowing for both local installation and seamless integration with cloud environments, providing users with the freedom to choose the best setup for their needs.
Seeking Alpha • May 14Simulations Plus: Reliance On Consulting And Acquisitions Creates DoubtsSummary Simulations Plus is benefiting from the growing use of computational tools in drug discovery, which would be boosted by the FDA Modernization Act 2.0. The biosimulation market is highly fragmented and underpenetrated, providing SLP with both organic and inorganic growth opportunities. While the company is operating in an attractive market and has a strong business, the company's valuation and growth prospects make the stock unappealing. Read the full article on Seeking Alpha
Recent Insider Transactions Derivative • May 09lead Independent Director notifies of intention to sell stockDaniel Weiner intends to sell 3k shares in the next 90 days after lodging an Intent To Sell Form on the 7th of May. If the sale is conducted around the recent share price of US$48.21, it would amount to US$157k. Since September 2023, Daniel's direct individual holding has increased from 7.70k shares to 10.01k. Company insiders have collectively sold US$297k more than they bought, via options and on-market transactions in the last 12 months.
Upcoming Dividend • Apr 22Upcoming dividend of US$0.06 per shareEligible shareholders must have bought the stock before 26 April 2024. Payment date: 06 May 2024. Payout ratio is a comfortable 46% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of American dividend payers (4.8%). Lower than average of industry peers (1.1%).
Declared Dividend • Apr 07Second quarter dividend of US$0.06 announcedDividend of US$0.06 is the same as last year. Ex-date: 26th April 2024 Payment date: 6th May 2024 Dividend yield will be 0.5%, which is lower than the industry average of 0.9%. Payout Ratios Payout ratio: 46%. Cash payout ratio: 38%.
